HM97211
/ Hanmi
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 05, 2019
Antitumor activity of novel reversible LSD1 inhibitor in preclinical models of AML and SCLC
(AACR 2019)
- "Collectively, results of this study suggested that novel reversible LSD1 inhibitor, HM97211 derivatives, can be a strong therapeutic agent for AML and SCLC patients. Hanmi presents a new insight to epigenetics application in anticancer therapy."
Preclinical
1 to 1
Of
1
Go to page
1